Rybelsus is Novo Nordisk's oral formulation of semaglutide for type 2 diabetes — the only oral GLP-1 RA currently approved (until Foundayo Q4 2026).
At a glance
- Generic name: oral semaglutide
- Manufacturer: Novo Nordisk
- List price (cash, no coverage): ~$968/mo
- Cash-pay program: NovoCare patient assistance
FDA-approved indications
- Type 2 diabetes (2019) — oral semaglutide formulation
Standard dosing
- Start: 3 mg daily × 30 days
- Then 7 mg daily; titrate to 14 mg if needed
- Take on empty stomach with sip of water; wait 30 min before food/other meds